{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T02:39:37Z","timestamp":1788316777396,"version":"build-2803163510"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T00:00:00Z","timestamp":1748217600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Rheumatoid arthritis (RA) poses a significant global health burden, especially among individuals aged 60 and older. This study analyzes RA burden trends using 2021 Global Burden of Disease (GBD) data.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Utilizing the GBD 2021 data, we extracted detailed metric on RA incidence, prevalence, mortality, and disability-adjusted life years (DALYs) specifically for those aged 60 and above. Linear regression analysis was applied to calculate the overall average annual percentage change (AAPC) spanning from 1990 to 2021. Furthermore, Joinpoint regression was employed to identify the years with the most significant changes in global trends. A nuanced stratified analysis was also performed, examining global trends across age groups, genders, and sociodemographic indices (SDI).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>From 1990 to 2021, both the age-standardized incidence rate (ASIR) and age-standardized prevalence rate (ASPR) of RA in people aged 60 and above worldwide has increased ASIR rose from 24.87 per 100,000 to 30.32 per 100,000 (95% uncertainty interval [UI] 19.83\u201342.38), while ASPR climbed from 635.51 per 100,000 to 726.91 per 100,000 (95% UI 634.05\u2013834.80). Conversely, the age-standardized death rate (ASDR) and age-standardized DALYs rate declined, with ASDR decreasing from 4.18 per 100,000 to 3.20 per 100,000 (95% UI 2.58\u20133.72), and DALYs rate dropping from 150.83 per 100,000 to 143.20 per 100,000 (95% UI 113.39\u2013178.43). Regionally, ASIR surged in North Africa and Middle East, Southeast Asia, and Andean Latin America, with ASPR peaking in Andean Latin America. Central Europe saw ASDR decline, while Central Asia\u2019s DALYs rate rose. Nationally, Vietnam\u2019s ASIR soared, and Ireland topped ASIR, ASPR, and DALYs rates. In 2021, for the global population aged 60 and above with RA: ASIR peaked at 65\u201369\u202fyears, ASPR peaked at 75\u201379\u202fyears; ASDR rose with age, and the age-standardized DALYs rate peaked at 85\u201389\u202fyears. Women bore a heavier RA burden. A non-linear SDI-DALYs relationship was noted, with Honduras and Mexico having high DALYs rates.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>From 1990 to 2021, the global ASIR and ASPR of RA increased among the older adult, while ASDR and age-standardized DALYs rate declined. Despite improvements, RA remains a public health priority, necessitating enhanced early diagnosis, treatment, and awareness, particularly among older adult women.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpubh.2025.1527680","type":"journal-article","created":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T04:10:36Z","timestamp":1748232636000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Global, regional, and national burdens of rheumatoid arthritis among people aged 60\u202fyears and older from 1990 to 2021: a trend analysis for the Global Burden of Disease Study 2021"],"prefix":"10.3389","volume":"13","author":[{"given":"Qin-Yi","family":"Su","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang-Yu","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng-Yuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Wen","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Xiao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,26]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"2857","DOI":"10.3390\/cells10112857","article-title":"Management of Rheumatoid Arthritis: an overview","volume":"10","author":"Radu","year":"2021","journal-title":"Cells"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1111\/1756-185X.12823","article-title":"Rheumatoid arthritis: past, present and future approaches to treating the disease","volume":"20","author":"Hyndman","year":"2017","journal-title":"Int J Rheum Dis"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"ITC1","DOI":"10.7326\/AITC201901010","article-title":"Rheumatoid arthritis","volume":"170","author":"Sparks","year":"2019","journal-title":"Ann Intern Med"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1007\/s10067-024-07083-3","article-title":"Trends and future projections of incidence rate and mortality of rheumatoid arthritis in China: a systematic analysis based on Gbd 2021 data","volume":"43","author":"Gu","year":"2024","journal-title":"Clin Rheumatol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"e594","DOI":"10.1016\/S2665-9913(23)00211-4","article-title":"Global, regional, and National Burden of rheumatoid arthritis, 1990-2020, and projections to 2050: a systematic analysis of the global burden of disease study 2021","volume":"5","author":"Collaborators","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"e0302140","DOI":"10.1371\/journal.pone.0302140","article-title":"Global burden of rheumatoid arthritis among adolescents and young adults aged 10-24 years: a trend analysis study from 1990 to 2019","volume":"19","author":"Li","year":"2024","journal-title":"PLoS One"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12041291","article-title":"The burden of rheumatoid arthritis: findings from the 2019 global burden of Diseases study and forecasts for 2030 by Bayesian age-period-cohort analysis","volume":"12","author":"Cai","year":"2023","journal-title":"J Clin Med"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1136\/annrheumdis-2013-204763","article-title":"The global burden of hip and knee osteoarthritis: estimates from the global burden of disease 2010 study","volume":"73","author":"Cross","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1136\/annrheumdis-2019-215142","article-title":"The world-wide burden of musculoskeletal Diseases: a systematic analysis of the World Health Organization burden of Diseases database","volume":"78","author":"Sebbag","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1136\/annrheumdis-2019-215920","article-title":"Global, regional and National Burden of rheumatoid arthritis 1990-2017: a systematic analysis of the global burden of disease study 2017","volume":"78","author":"Safiri","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"e005383","DOI":"10.1136\/rmdopen-2024-005383","article-title":"Global, regional and National Trends in the epidemiology of rheumatoid arthritis from 1990 to 2021: an age-period-cohort effect analysis of the global burden of disease study 2021","volume":"11","author":"Tang","year":"2025","journal-title":"RMD Open"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"103450","DOI":"10.1016\/j.autrev.2023.103450","article-title":"Age-standardized incidence, prevalence, and mortality rates of autoimmune Diseases in women of childbearing age from 1990 to 2019","volume":"22","author":"Cao","year":"2023","journal-title":"Autoimmun Rev"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1186\/s12889-024-19290-3","article-title":"Age-standardized incidence, prevalence, and mortality rates of autoimmune Diseases in adolescents and young adults (15-39 years): an analysis based on the global burden of disease study 2021","volume":"24","author":"Zhao","year":"2024","journal-title":"BMC Public Health"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.5114\/aoms\/183955","article-title":"Global, regional, and National Burdens of rheumatoid arthritis in young adults from 1990 to 2019","volume":"20","author":"Zhang","year":"2024","journal-title":"Arch Med Sci"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"101033","DOI":"10.1016\/j.waojou.2025.101033","article-title":"Trend analysis and Cross-National Inequity Analysis of immune-mediated inflammatory Diseases in children and adolescents aged 10-24 from 1990 to 2021","volume":"18","author":"Xu","year":"2025","journal-title":"World Allergy Organ J"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1080\/03009742.2024.2312693","article-title":"Population-based epidemiological projections of rheumatoid arthritis in Germany until 2040","volume":"53","author":"Wang","year":"2024","journal-title":"Scand J Rheumatol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1016\/S0140-6736(24)00757-8","article-title":"Global incidence, prevalence, years lived with disability (Ylds), disability-adjusted life-years (Dalys), and healthy life expectancy (Hale) for 371 Diseases and Injuries in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the global burden of disease study 2021","volume":"403","year":"2024","journal-title":"Lancet"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1007\/s10067-023-06628-2","article-title":"Estimation of the global prevalence, incidence, years lived with disability of rheumatoid arthritis in 2019 and forecasted incidence in 2040: results from the global burden of disease study 2019","volume":"42","author":"Shi","year":"2023","journal-title":"Clin Rheumatol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.yfrne.2014.04.004","article-title":"Gender differences in autoimmune disease","volume":"35","author":"Ngo","year":"2014","journal-title":"Front Neuroendocrinol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1111\/j.1749-6632.2002.tb04210.x","article-title":"Androgens and estrogens modulate the immune and inflammatory responses in rheumatoid arthritis","volume":"966","author":"Cutolo","year":"2002","journal-title":"Ann N Y Acad Sci"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1177\/07334648231163052","article-title":"Trajectories of successful aging among older adults in Aotearoa New Zealand","volume":"42","author":"Fasoro","year":"2023","journal-title":"J Appl Gerontol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/S0140-6736(25)00397-6","article-title":"Global, regional, and National Prevalence of child and adolescent overweight and obesity, 1990-2021, with forecasts to 2050: a forecasting study for the global burden of disease study 2021","volume":"405","year":"2025","journal-title":"Lancet"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1136\/annrheumdis-2017-211569","article-title":"Obesity and rates of clinical remission and low Mri inflammation in rheumatoid arthritis","volume":"76","author":"George","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1080\/1744666X.2022.2106970","article-title":"Epidemiology of rheumatoid arthritis: genetic and environmental influences","volume":"18","author":"Venetsanopoulou","year":"2022","journal-title":"Expert Rev Clin Immunol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s00281-022-00912-0","article-title":"Genetics of rheumatoid arthritis","volume":"44","author":"Padyukov","year":"2022","journal-title":"Semin Immunopathol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1016\/S0140-6736(18)32225-6","article-title":"Regional, and National Comparative Risk Assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990-2017: a systematic analysis for the global burden of disease study 2017","volume":"392","year":"2018","journal-title":"Lancet"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1016\/S0140-6736(17)30819-X","article-title":"Smoking prevalence and attributable disease burden in 195 countries and territories, 1990-2015: a systematic analysis from the global burden of disease study 2015","volume":"389","author":"Collaborators","year":"2017","journal-title":"Lancet"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1111\/imj.15537","article-title":"Rheumatoid arthritis is a preventable disease: 11 ways to reduce your Patients' risk","volume":"52","author":"Koller-Smith","year":"2022","journal-title":"Intern Med J"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"e000057","DOI":"10.1136\/rmdopen-2015-000057","article-title":"Rheumatoid arthritis treatment: the earlier the better to prevent joint damage","volume":"1","author":"Monti","year":"2015","journal-title":"RMD Open"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1136\/annrheumdis-2013-204573","article-title":"Eular recommendations for the Management of Rheumatoid Arthritis with synthetic and biological disease-modifying Antirheumatic drugs: 2013 update","volume":"73","author":"Smolen","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"ref31","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.18688.1","article-title":"Emerging therapies in rheumatoid arthritis: focus on monoclonal antibodies","volume-title":"F1000Res","author":"Senolt","year":"2019"},{"key":"ref32","year":"2021"},{"key":"ref33","first-page":"1245","article-title":"Diagnosis and management of rheumatoid arthritis","volume":"84","author":"Wasserman","year":"2011","journal-title":"Am Fam Physician"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2025.1527680\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T04:10:37Z","timestamp":1748232637000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2025.1527680\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,26]]},"references-count":33,"alternative-id":["10.3389\/fpubh.2025.1527680"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2025.1527680","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,26]]},"article-number":"1527680"}}